Table 1.
Demographic data.
| DPP-4i(–) (n = 1,083) | DPP-4i(+) (n = 1,083) | ||||
|---|---|---|---|---|---|
| N | (%) | N | (%) | p-values | |
| Age, mean | 60.41 | (11.05) | 59.49 | (10.84) | 0.052 |
| <40 | 38 | (3.5) | 42 | (3.9) | 0.449 |
| 40–59 | 507 | (48.6) | 519 | (47.9) | |
| ≥60 | 538 | (49.7) | 522 | (48.2) | |
| Gender | |||||
| Female | 535 | (49.4) | 529 | (48.8) | 0.796 |
| Male | 548 | (50.6) | 554 | (51.2) | |
| Insurance range | |||||
| < NTD. 15,840 | 501 | (46.3) | 494 | (45.6) | 0.932 |
| NTD. 15,840–NTD. 25,001 | 356 | (32.9) | 364 | (33.6) | |
| >NTD. 25,001 | 226 | (20.9) | 225 | (20.8) | |
| Comorbidities | |||||
| HBV | 234 | (21.6) | 257 | (23.7) | 0.238 |
| Liver cirrhosis | 858 | (79.2) | 857 | (79.1) | 0.958 |
| Other antidiabetic medications | |||||
| Sulfonylureas | 619 | (57.2) | 627 | (57.9) | 0.728 |
| Metformin | 725 | (66.9) | 698 | (64.5) | 0.222 |
| Pioglitazone | 107 | (9.9) | 119 | (11.0) | 0.399 |
| Acarbose | 191 | (17.6) | 192 | (17.7) | 0.955 |
| Meglitinides | 86 | (7.9) | 89 | (8.2) | 0.813 |
| Insulin | 59 | (5.4) | 74 | (6.8) | 0.179 |
| Anti-HCV agents | 73 | (6.7) | 84 | (7.8) | 0.362 |
| Duration of diabetes (months) | |||||
| <36 | 299 | (27.6) | 311 | (28.7) | 0.566 |
| ≥36 | 784 | (72.4) | 772 | (71.3) | |
DPP-4i(–), non-dipeptidyl peptidase 4 inhibitor cohort; DPP-4i(+), dipeptidyl peptidase 4 inhibitor cohort; NTD, New Taiwan Dollar; HBV, hepatitis B virus; HCV, hepatitis C virus. Age is shown as geometric mean.